Caribou Biosciences : Regulation FD Presentation - Form 8-K

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or... | March 29, 2023

Related Keywords

United States ,Berkeley ,California ,New York ,Samy Figueroa ,Peggy Vorwald ,Sundar Jagannath ,Rachel Haurwitz ,Excellence At Tisch Cancer Institute ,Myeloma Center ,Mount Sinai School Of Medicine ,Caribou Biosciences Inc ,Exchange Commission ,Nasdaq ,Caribou Biosciences Announces Dosing ,First Patient ,Refractory Multiple Myeloma ,Mount Sinai ,Mount Sinai School ,Multiple Myeloma Center ,Tisch Cancer Institute ,Mount Sinai Hospital ,Caribou Biosciences ,Private Securities Litigation Reform Act ,Annual Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Caribou ,Iosciences ,Nnounces ,Closing ,F ,First ,Patient ,N ,The ,Ammouflage ,Hase , ,Trial ,Allogeneic ,Fell ,Therapy ,Or ,Treatment ,Elapsed Crbu Us1420381089 ,